 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Prostate Cancer
| ABX-EGF |
Anti-EGF monoclonal antibody |
Abgenix and Amgen |
II |
| Actimed |
Immunomodulatory analog |
Celgene |
II |
| Alanosine |
Amino acid analog |
Triangle |
II |
| AMD-473 |
Platinum |
AnorMed |
II |
| Aptosyn (exisulind) |
Selective apoptotic antineoplastic drug (SAAND) |
Cell Pathways |
II |
| Atrasentan |
Anti-autocrine endothelin protein |
Abbott Laboratories |
FDA did not approve 09-13-05 |
| Avodart (dutasteride) |
4-azasteroid compound |
GlaxoSmithKline |
III |
| Ceplene (histamine) |
Synthetic nucleoside analog |
Maxim Pharmaceuticals |
II |
| CG7870 |
Oncolytic virus |
Cell Genesys |
I |
| CP461 |
Apoptotic antineoplastic |
Cell Pathways |
II |
| DCVax-Prostate |
Vaccine |
Northwest Biotherapeutics |
III |
| DN-101 (calcitriol) |
Vitamin D |
Aventis |
II |
| Fareston (toremifene) |
Anti-estrogen |
Orion |
II |
| Flurizan (flurbiprofen) |
Non-steroidal anti-inflammatory agent |
Myriad Genetics |
II |
| GBC 590 |
Lecithin inhibitor |
Glycol Genesys |
I |
| G1198745 (dutasteride) |
MoAB alpha reductase inhibitor |
GlaxoSmithKline |
II |
| GNRH Pharmaccine |
Anti-GnRH immunogen |
GlaxoSmithKline Aphton |
II |
| GPI-0100 |
Vaccine adjuvant |
Galenica Pharmaceuticals |
I |
| GTI-2501 |
Antisense therapy |
Lorus Therapeutics |
II |
| GVAX |
Vaccine |
Cell Genesys |
I |
| Histrelin |
Gonadotropin releasing hormone antagonist |
Shire Pharmaceuticals Group |
III |
| Irofulven |
Hydroxymethylacylufene |
MGI |
II |
| Lowpromaxx 28 day |
|
Epic Therapeutics |
II |
| MDX-010 |
Anti-CTLA-4 antibody |
Medarex |
II |
| MDX-070 |
PSMA inhibitor |
Medarex |
II |
| MLN 2704 |
Monoclonal antibody |
Millennium |
I/II |
| MLN591RL |
Monoclonal antibody |
Millennium |
II |
| MVA-MUC1-IL2 |
Gene therapy |
Transgene |
II |
| NBI-42902 |
GnRH receptor antagonist |
Neurocrine Biosciences |
II |
| Norelin |
Vaccine |
Pfizer |
I |
| Omnitarg (Pertuzumab) |
HER2 directed monoclonal antibody |
Genentech, Roche |
II |
| Onconase (ranpirnase) |
Ribonuclease |
Alfacell |
II |
| OGX-011 |
Cuterin inhibitor |
OncoGenex |
I |
| Panzem (2-methoxyestradiol) |
Estrogen |
EntreMed |
II |
| Phenaxodil PXD |
Chemosensitizer |
Marshall Edwards |
I |
| Prostvac-VF |
Vaccine |
Therion Biologics |
II |
| Provenge |
Vaccine |
Dendreon |
III |
| PSMA Vaccine |
Vaccine |
Cytogen Progenics |
I |
| Satraplatin |
Platinum compound |
Spectrum Pharmaceuticals |
III |
| Squalamine |
Anti-angiogenic |
Genaera |
II |
| SR 31747 |
Peripheral sigma ligand |
Sanofi-Synthelabo |
II |
| SR 48692 |
Neurotensin antagonist |
Sanofi-Synthelabo |
II |
| SU101 |
TKI PDGFR inhibitior |
Pfizer |
III |
| Taxoprexin (docosahexaenoic acid-paclitaxel) |
Taxane |
Protarga |
II |
| Taxotere (docetaxel) |
Taxoid |
Aventis |
II |
| Tesmilifene |
Chemoprtoector |
YM Biosciences |
II |
| Thalomid (thalidomide) |
Immunomodulator |
Celgene |
III |
| Thermo Dox |
Heat activated liposomal doxorubicin |
Celsio |
I |
| Triapine |
Ribonucleotide reductase inhibitor |
Vio Eli Lilly |
II |
| Vitaxin |
MoAb |
MedImmune |
II |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
